

# Contents

Preface . . . . .	V
Contributors . . . . .	X

## Chronic Concern on Chronic Toxicity Studies

<b>Chronic toxicity tests, current problems and possible solutions</b>	
Zbinden, G. . . . .	1
<b>What can be gained from a retrospective analysis of chronic toxicity studies?</b>	
Walker, S. R. . . . .	7
<b>The role of carcinogenicity studies in risk assessment</b>	
Fröhlich, E., Hess, R. . . . .	13
<b>Alternatives to chronic toxicity studies</b>	
Baß, R., Grosdanoff, P., Lehnert, T. . . . .	21

## Clinical Trials and Medical Practice

<b>What good are clinical trials?</b>	
Fell, P. J. . . . .	27
Discussion . . . . .	38
<b>Clinical guidelines – a help or a hindrance?</b>	
Dukes, M. N. G. . . . .	39
Discussion . . . . .	44
<b>Clinical trials in the natural environment</b>	
Lasagna, L. . . . .	45
Discussion . . . . .	49
<b>Clinical trials and the general practitioner</b>	
Lucchelli, P. E. . . . .	51
Discussion . . . . .	56
<b>Clinical trials and chronic diseases</b>	
Fülgraff, G. . . . .	57
Discussion . . . . .	63
<b>Alternatives to clinical trials in post-marketing research on drug effects</b>	
Miettinen, O. S. . . . .	65
Discussion . . . . .	68

## **The Future of Long-Term Intervention and Prevention Studies**

<b>The future of long-term intervention and prevention studies – methodological aspects</b>	
Epstein, F. H. . . . .	69
Discussion . . . . .	76
<b>Lessons for the future from long-term studies with beta blockers and hypolipidaemic agents</b>	
Fitzgerald J. D. . . . .	77
Discussion . . . . .	87
<b>Rauwolfia derivatives and breast cancer: how do we know when we have the answers?</b>	
Joyce, C. R. B. . . . .	89
<b>The organisation of long-term intervention and prevention studies</b>	
Rawlins, M. D. . . . .	109
Discussion . . . . .	112

## **New Biostatistical Concepts for Clinical Trials**

<b>The explanatory and pragmatic approaches in clinical trials</b>	
Schwartz, D., Pejovic, M. . . . .	113
<b>Alternatives to classical randomized trials</b>	
Zelen, M. . . . .	121
Discussion . . . . .	129
<b>Data quality assurance with particular regard to protocol violations</b>	
Vanderbeke, O., Blomer, R. . . . .	131
Discussion . . . . .	137

## **Clinical Trials in Children**

<b>The need of clinical drug trials in children</b>	
Reinhardt, D. . . . .	139
<b>Ethical restrictions in clinical trials in children</b>	
Boréus, L. O. . . . .	151
Panel discussion: clinical trials in children . . . . .	157

## **European Drug Registration**

<b>The role of the EEC in the harmonisation of drug registration</b>	
Teijgeler, C. A. . . . .	165
<b>Clinical trials – European recommendations</b>	
Alexandre, J.-M. . . . .	175
Discussion . . . . .	178
Panel discussion: international acceptance of data . . . . .	179

## **Special Lecture**

<b>The Pharmaceutical Industry – research and responsibility</b>	
Gareis, H. . . . .	195
<b>Subject index</b>	
Subject index . . . . .	205